What are the treatment options for beta-thalassemia patients with osteoporosis? A Cochrane Review summary with commentary.
作者信息
Arman Sina
机构信息
Department of Physical Medicine and Rehabilitation, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
出版信息
J Musculoskelet Neuronal Interact. 2024 Jun 1;24(2):103-106.
Abstract
摘要
相似文献
1
What are the treatment options for beta-thalassemia patients with osteoporosis? A Cochrane Review summary with commentary.骨质疏松症的β地中海贫血患者有哪些治疗选择？一项Cochrane系统评价总结及述评。
J Musculoskelet Neuronal Interact. 2024 Jun 1;24(2):103-106.
2
Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis.地舒单抗对比唑来膦酸治疗β-地中海贫血所致骨质疏松症患者。
Medicine (Baltimore). 2020 Dec 18;99(51):e23637. doi: 10.1097/MD.0000000000023637.
3
Management of beta-thalassemia-associated osteoporosis.β-地中海贫血相关性骨质疏松症的管理。
Ann N Y Acad Sci. 2016 Mar;1368(1):73-81. doi: 10.1111/nyas.13041. Epub 2016 Apr 6.
4
[Should we treat thalassemia-induced osteoporosis: two case reports].[我们应该治疗地中海贫血所致骨质疏松症吗：两例报告]
Praxis (Bern 1994). 2012 Oct 3;101(20):1325-9. doi: 10.1024/1661-8157/a001076.
5
Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review.唑来膦酸治疗地中海贫血相关性骨质疏松症后骨恢复情况：荟萃分析和系统评价。
Osteoporos Int. 2010 Jan;21(1):183-7. doi: 10.1007/s00198-009-0875-4. Epub 2009 Feb 26.
6
Pathogenesis and management of osteoporosis in thalassemia.地中海贫血中骨质疏松症的发病机制与管理
Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:86-93.
7
Treatment for osteoporosis in people with ß-thalassaemia.β地中海贫血患者骨质疏松症的治疗
Cochrane Database Syst Rev. 2016 Mar 10;3:CD010429. doi: 10.1002/14651858.CD010429.pub2.
8
Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy.每3个月与每年静脉注射唑来膦酸对低骨密度β地中海贫血患者的疗效回顾性比较
Med Arch. 2018 Jun;72(3):170-173. doi: 10.5455/medarh.2018.72.170-173.
9
Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.雷奈酸锶对重型地中海贫血相关骨质疏松症女性骨量和骨转换的影响。
J Bone Miner Metab. 2016 Sep;34(5):540-6. doi: 10.1007/s00774-015-0689-8. Epub 2015 Jul 24.
10
Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.唑来膦酸对β地中海贫血骨质疏松症患者骨转换标志物和骨密度的影响。
Ann Hematol. 2007 Jan;86(1):23-30. doi: 10.1007/s00277-006-0180-7. Epub 2006 Sep 30.
本文引用的文献
1
Endocrinopathies in beta thalassemia: a narrative review.β地中海贫血中的内分泌病：一项叙述性综述。
Hormones (Athens). 2024 Jun;23(2):205-216. doi: 10.1007/s42000-023-00515-w. Epub 2023 Dec 16.
2
Association of osteoporosis and sarcopenia with fracture risk in transfusion-dependent thalassemia.输血依赖型地中海贫血中骨质疏松症和肌少症与骨折风险的关系。
Sci Rep. 2023 Sep 29;13(1):16413. doi: 10.1038/s41598-023-43633-6.
3
The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial.阿仑膦酸钠治疗地中海贫血相关性骨质疏松症的疗效：一项随机对照试验。
Front Endocrinol (Lausanne). 2023 May 10;14:1178761. doi: 10.3389/fendo.2023.1178761. eCollection 2023.
4
Treatment for osteoporosis in people with beta-thalassaemia.β-地中海贫血患者骨质疏松的治疗。
Cochrane Database Syst Rev. 2023 May 9;5(5):CD010429. doi: 10.1002/14651858.CD010429.pub3.
5
Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.β 地中海贫血所致骨质疏松症的管理方法-重新审视长期存在的关系。
Acta Biomed. 2022 Oct 26;93(5):e2022305. doi: 10.23750/abm.v93i5.13668.
6
2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia.2021年地中海贫血国际联合会输血依赖型地中海贫血管理指南
Hemasphere. 2022 Jul 29;6(8):e732. doi: 10.1097/HS9.0000000000000732. eCollection 2022 Aug.
7
Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience.特立帕肽治疗β-地中海贫血相关性骨质疏松症的疗效和安全性：真实世界经验。
Calcif Tissue Int. 2022 Jul;111(1):56-65. doi: 10.1007/s00223-022-00963-3. Epub 2022 Mar 4.
8
β-Thalassemias.β地中海贫血
N Engl J Med. 2021 Feb 25;384(8):727-743. doi: 10.1056/NEJMra2021838.
9
Pathogenesis of Thalassemia Major-associated Osteoporosis: A Review with Insights from Clinical Experience.重型地中海贫血相关骨质疏松症的发病机制：基于临床经验的综述
J Clin Res Pediatr Endocrinol. 2019 May 28;11(2):110-117. doi: 10.4274/jcrpe.galenos.2018.2018.0074. Epub 2018 Jul 11.
10
Bone disease in β thalassemia patients: past, present and future perspectives.β 地中海贫血患者的骨骼疾病：过去、现在和未来的观点。
Metabolism. 2018 Mar;80:66-79. doi: 10.1016/j.metabol.2017.09.012. Epub 2017 Oct 4.
Zotero 插件